Immunovant says IMVT-1402 cutaneous lupus study misses primary endpoint, halts CLE development

Bitget2026/09/23 11:06

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Immunovant reported topline results from a proof-of-concept trial of IMVT-1402 in cutaneous lupus erythematosus.
The study missed its primary goal, prompting Immunovant to halt development of IMVT-1402 in this indication.
Results showed favorable directional signals on several measures, with stronger antibody reductions linked to better clinical responses.
Safety and tolerability remained consistent with prior studies, with no new concerns highlighted.
Other IMVT-1402 development programs remain on schedule across multiple autoimmune diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunovant Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609230700PRIMZONEFULLFEED9832130) on September 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Immunovant says IMVT-1402 cutaneous lupus study misses primary endpoint, halts CLE development

You may also like

Crypto prices